Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
Arms and Interventions
|Experimental: TearCare Group (Study Device)|
Device: TearCare System
TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
|Active Comparator: Restasis Group (Control)|
Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
Primary Outcome Measures
- Tear Break-Up Time [6 months]
Mean Change from baseline in Tear Break-Up Time (TBUT)
- OSDI Score [6 months]
Mean Change from baseline in OSDI score
At least 22 years of age
Reports dry eye symptoms within the past 3 to 6 months
Reports having to use artificial tears or lubricants regularly over the past month to relieve dry eye symptoms.
Schirmer tear test (with anesthesia) ≥1 to ≤10 mm in 5 minutes
OSDI Score of 23-79
TBUT of ≥1 to ≤7 seconds in both eyes
Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score ≤12 in each eye.
At least 15 glands in each lower eyelid should be expressible, with a sterile cotton swab, at the slit lamp.
Best corrected visual acuity of 20/100 or better in both eyes.
Willing and able to comply with the study procedures and follow-up
Willing and able to provide informed consent
- Use of any of the following medications:
Cyclosporine (Restasis, Cequa etc.) or Xiidra within 60 days prior to enrollment;
Antihistamines (oral or topical) within 10 days prior to enrollment;
Systemic medication(s) (other than antihistamines) that is known to cause ocular dryness (e.g. diuretics, anti-hypertensives, anti-depressants, hormone therapy) and whose dose of this medication(s) has not been stable within 30 days prior to enrollment. There must be no anticipated adjustments to the dose of these medications for the duration of the trial;
Accutane (at any time);
Oral tetracyclines or azithromycin within 30 days prior to enrollment; or
Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, non-steroidal anti- inflammatory medications within 30 days prior to enrollment.
- Any of the following dry eye treatments:
Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [Lipiflow], iLux etc.) within 12 months prior to enrollment either as part of routine care or clinical investigation;
Meibomian gland expression within 6 months prior to enrollment;
Blephex or debridement within 3 months prior to enrollment is an exclusion;
Punctal occlusion or punctal plugs. Investigators can choose to remove the punctal plugs 15 days prior to enrollment;
Use of TrueTear device within the past 2 weeks. (Subjects must refrain from using the TrueTear device for the duration of the study.); or
Any history of meibomian gland probing
History of eyelid, conjunctiva or corneal surgery (including refractive surgery) within the past year. In addition, subjects with any history of the following are excluded: chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery.
Contact lens use within the past 2 weeks.
History of Ocular Herpes Simplex or Ocular Herpes Zoster
Any active, clinically significant ocular or peri-ocular infection or inflammation
Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to enrollment
Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded.
Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis).
Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area.
Contacts and Locations
|1||Doctor My Eyes||Scottsdale||Arizona||United States||85254|
|2||Scripps Health||La Jolla||California||United States||92037|
|3||Harvard Eye Associates||Laguna Hills||California||United States||92653|
|4||Eye Research Foundation||Newport Beach||California||United States||92663|
|5||Vision Institute||Colorado Springs||Colorado||United States||80907|
|6||Loh Ophthalmology Associates||Miami||Florida||United States||33143|
|7||Jackson Eye||Lake Villa||Illinois||United States||60046|
|8||Cincinnati Eye Institute||Edgewood||Kentucky||United States||41017|
|9||Kentucky Eye Institute||Lexington||Kentucky||United States||40517|
|10||Vita Eye Clinic||Shelby||North Carolina||United States||28150|
|11||Vantage Eye Care||Bala-Cynwyd||Pennsylvania||United States||19004|
|12||University of Pittsburg-Ophthalmology Dept||Pittsburgh||Pennsylvania||United States||15213|
|13||Vance Thompson Vision||Sioux Falls||South Dakota||United States||57108|
|14||Parkhurst NuVision||San Antonio||Texas||United States||78229|
Sponsors and Collaborators
- Sight Sciences, Inc.
Study Documents (Full-Text)None provided.